Use of LVV-hemorphin-6 and optionally AF12198 as therapeutic agent(s) - AU2008297915

ABSTRACT & PATENT DETAILS
Inventor/s:
  • Bacher, Gerald
  • Bevec, Dorian
  • Cavalli, Fabio
  • Cavalli, Vera
Assignee/s:
  • mondoBIOTECH Laboratories AG

WO 2009/033741 PCT/EP2008/007680 1 Use of a peptide as a therapeutic agent Specification 5 The present invention is directed to the use of the peptide compound Leu-Val-Val Tyr-Pro-Trp-Thr-Gln-Arg-OH (Leu-Valorphin-Arg) as a therapeutic agent for the prophylaxis and/or treatment of cancer, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an autoimmune disease, or a 10 heart and vascular disease. Background of the invention The identification of a therapeutic compound effective for the prophylaxis and/or treatment of a disease can be based on the activity of the compound in a biological 15 assay. A biological assay that mimics a disease causative mechanism can be used to test the therapeutic activity of a candidate peptide. The causative mechanism of many diseases is the over activity of a biological pathway. A peptide that can reduce the activity of the biological pathway can be 20 effective in the prophylaxis and/or treatment of the disease caused by the over activity of the biological pathway. Similarly the causative mechanism of many diseases is the over production of a biological molecule. A peptide that can reduce the production of the biological molecule or block the activity of the over produced biological molecule can be effective in the prophylaxis and/or treatment of the 25 disease caused by the over production of the biological molecule. Conversely, the causative mechanism of many diseases is the under activity of a biological pathway. A peptide that can increase the activity of the biological pathway can be effective in the prophylaxis and/or treatment of the disease caused by the 30 under activity of the biological pathway. Also similarly the causative mechanism of many diseases is the under production of a biological molecule. A peptide that can increase the production of the biological molecule or mimic the biological activity of the under produced biological molecule can be effective in the prophylaxis and/or treatment of the disease caused by the under production of the biological molecule. 35 It is the object of the present invention to provide a peptide compound for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.

This page contains all relevant details related to patent number AU2008297915. This patent was filed on 09/09/2008 and has a status of LAPSED. The inventors associated with this patent are:

  • Bacher, Gerald
  • Bevec, Dorian
  • Cavalli, Fabio
  • Cavalli, Vera

The applicant/owner of the patent is registered as mondoBIOTECH Laboratories AG. They used the patent attorney firm Spruson & Ferguson to file this.

Australian patent AU2008297915 is one of over a million that we feature on IP in Australia which covers the entire spectrum of patents in Australia. mondoBIOTECH Laboratories AG is also one of thousands of applicants we’ve analysed. We also understand who are the most prolific inventors in Australia with details on all the patents attributed to individuals.

Because we have insights into all the attorney firms that have been used across Australia including which specific patent attorney worked on each patent, we have access to unique analytics on the best attorney to use if you have specific patent needs i.e. it would make sense that the patent attorney you should use for your invention is the one who is most active and has the most experience in your technology area.

Filing patents is a time consuming and expensive exercise which is why care needs to be taken ensuring that you’re working with the right individual.

Because we’re an independent third party we can give you unbiased insights and recommendations on the right partner to choose. For more information contact us
Publications
Vol/Iss Pub. Date Publication Action Reason
26/36 20/09/2012 Patent Lapsed Did not ask for an examination within the prescribed time.
24/15 15/04/2010 National Phase Entry

Last Updated: 15/08/2013



Claims

Claims 1. Peptide having the formula Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-OH for use in medicine. 5 2. Peptide according to claim 1 in combination with peptide having the formula Phe-Glu-Trp-Thr-Pro-Gly-Tyr-Trp-Gln-Pro-Tyr-Ala-Leu-Pro-Leu-OH for use in medicine. 10 3. Combination of the peptides Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-OH and Phe Glu-Trp-Thr-Pro-Gly-Tyr-Trp-Gln-Pro-Tyr-Ala-Leu-Pro-Leu-OH and salts and hydrates thereof. 4. Combination according to claim 3, wherein the peptides are contained in the 15 combination in an amount from 30% by weight to 70% by weight to 70% by weight to 30% by weight. 5. Combination according to claim 3 or 4 for use in medicine. 20 6. Use of the peptide according to claim 1 or 2 or the combination according to claim 3 or 4 or 5 for the manufacture of a pharmaceutical composition for treatment and/or prophylaxis of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. ?5 7. Use of the peptide according to claim 6, wherein infectious disease is selected from Mycobacterium tuberculosis infection and infectious diseases caused by Mycobacterium tuberculosis infection selected from infectious diseases in the lung, of the central nervous system, in the lymphatic system, in the circulatory 30 system, in the genitourinary system, of the bones, joints, and skin. 8. Use of the peptide according to claim 1 or 2 or the combination according to claim 3 or 4 or 5 for the preparation of a formulation for oral administration to newborns, toddlers, and/or infants. 35 9. Use of the peptide according to claim 1 or 2 or the combination according to claim 3 or 4 or 5 for the preparation of a lyophilized formulation or a buffered liquide formulation.WO 2009/033741 PCT/EP2008/007680 107 10. Pharmaceutical composition containing the peptide according to claim 1 or the combination according to claim 3 together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. 5 11. Pharmaceutical composition according to claim 9 in the form of a lyophilisate or liquide buffer solution. 12. Pharmaceutical composition according to claim 10 or 11 suitable for intravenous administration, oral administration, or for administration by inhalation. 10 13. Pharmaceutical composition according to claim 10, 11 or 12 in the form of an artificial mother milk formulation or mother milk substitute suitable for oral delivery to newborns, toddlers and infants. 15 14. Pharmaceutical composition according to claim 10, 11, 12 or 13 suitable for the treatment and/or prophylaxis of cancer, an autoimmune disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an infectious disease, a lung disease, a heart and vascular disease or a metabolic disease. 20 15. Method for treating cancer, an autoimmune disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an infectious disease, a lung disease, a heart and vascular disease or a metabolic disease in a mammal, including a human, which comprises administering to the mammal a pharmaceutically effective amount of the peptides Leu-Val-Val-Tyr-Pro-Trp-Thr 25 Gln-Arg-OH or salts and hydrates thereof effective to treat the cancer, the autoimmune disease, the fibrotic disease, the inflammatory disease, the neurodegenerative disease, the infectious disease, the lung disease, the heart and vascular disease or the metabolic disease.